Germaine Fuh

Curriculum Vitae
Germaine Fuh
SUMMARY
25+ years in Genentech Research
50 coauthored papers (as corresponding author in 14)
13 issued patents and 10 published patent applications
30 invited oral presentations in outside conferences
AWARD/RECOGNITION
2009 Ralph Schwall Inventor Memorial Award at Genentech
Two-in-One antibodies listed by MIT Technology Review as important emerging technology in 2010
PROFESSIONAL EXPERIENCE
Senior Scientist (2009-present), Scientist (2003-2009), Antibody Engineering and Protein
Engineering Dept., Genentech
Dual action Fab (DAF) two-in-one antibodies
• Invent the concept and demonstrate the generation of DAF with high dual affinity
• HER2/VEGF dual-specific antibody is proof of concept, the first report of such antibody
• Collaborate and lead antibody efforts to develop EGFR/HER3 DAF for therapeutics
• Initiated alternative DAF strategy with IL4/5 DAF development (in progress)
Coordinate cross dept team developing Dual and Bi-specific antibody platforms
• Lead and coordinate multiple groups to validate formats and platforms
Synthetic antibody phage libraries
• Demonstrate the unique utility of phage library-derived antibody with the cross-species
(human/rodent) VEGF-A and BR3 blocking antibodies development and contribute in team
effort to develop these antibodies as therapeutic candidates
• Design, generate and transfer the antibody phage libraries and affinity improvement
method for antibody discovery
Associate Scientist (1999-2003), Protein Engineering Dept., Genentech
Synthetic Antibody Phage Libraries:
• Design bivalent template formats and diversity of synthetic Fab phage library that allow
fast and nimble antibody discovery
• Demonstrate the first proof of concept of libraries which mimic natural diversity
• Design and implement affinity improvement strategies for phage-derived antibodies
• Develop the processes for high throughput generation of antibodies from phage library:
library generation and storage, selection and screening
• Discover and developed blocking anti-mVEGF, which provide alternative anti-VEGF for
development which is widely used for VEGF research in mouse through collaboration
Phage Technology
1

• Develop C-terminal p8 phage display, applied in PDZ interaction studies
• Develop C-terminal p3 phage display
VEGF biology
• Discover neuropilin/Flt1 interaction and its relationship with KDR and VEGF
Senior Research Associate (1993-1999), Research Associate (1986-1993)
VEGF/receptors Biochemistry
• Define the requirements for signaling through VEGF receptors using engineered VEGF
variants and dissect the avidity of binding dimeric VEGF
• Design and produce VEGF receptor ECD for structure and function analysis.
• Characterize the neuropilin/VEGF165 interaction and its mechanism in regulating the
function of KDR
HGH/receptors Biochemistry
• Demonstrate the sequential dimerization of hGHr and PRLr and the action of hGH
antagonist
• Explore hPRLr ligand antagonists for breast cancer
• Develop PEGylated hGH to extend half life in vivo
• Express, purify and characterize the hGHbp and hPRLbp from E. coli
• Develop small molecule screening assay for hGH antagonist
Aspartame (NutraSweet) bioengineering
• Purify and characterize enzymes for biosynthetic pathways achieving 1.5 M Benchmark
Analytical Chemist, Watson Inc. S. San Francisco, 1984-1985
• Developed quantitative HPLC methods for small molecule drugs.
• Trained and managed three lab technicians.
Research Associate/Graduate student, UC San Francisco, 1982-1984
• Characterize extracellular matrix proteins and mechanism of cancer metastasis.
Research Assistant, National Yang-Ming Medical College, Taiwan, 1980-1982
• With Dr. Wu-Jer Liu, study Herpes Simplex virus type II from cervical cancer patients
EDUCATION
UC San Francisco M.S., Laboratory Sciences 1982-84
National Taiwan Univ. B.S., Medical Technology 1976-80
PUBLICATION
1. Kim, H. S., Ernst, J.A., Brown, C., Bostrom, J., Fuh, G., Lee, C. V., Huang, A., Vandlen, R. L.,
Yansura, D. G. (2012) Translation levels control multi-spanning membrane protein expression.
PLoS One 7, e35844
2. Schaefer, G., Haber, L., Crocker, L. M., Shia, S., Shao, L., Dowbenko, D., Totpal, K., Wong, A.,
Lee, C. V., Stawicki, S., Clark, R, Fields C, Lewis Phillips GD, Prell RA, Danilenko DM,
Franke Y, Stephan JP, Hwang J, Wu Y, Bostrom J, Sliwkowski MX, Fuh, G., Eigenbrot, C.
(2011) A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity
Compared with Monospecific Antibodies. Cancer Cell 20:472-86.
3. Koenig, P., Fuh, G. (2011) Two-in-One antibodies. In: Roland E. Kontermann (ed) Bispecific
2

antibodies. Springer-Verlag, pp. 187-198.
4. Bostrom, J., Haber, L, Koenig, P., Kelley, RF, Fuh, G. (2011) High Affinity Antigen Recognition
of the Dual Specific Variants of Herceptin Is Entropy-Driven in Spite of Structural Plasticity.
PLosOne 6, 1-12.
5. Singh, M., Lima, A., Molina, R, Hamilton, P, Clermont, A. C., Devasthali, V., Thompson, J. D.,
Cheng, J. H., Bou Reslan, H, Ho, C. C., Cao, T. C., Lee, C. V., Nannini, M. A., Fuh, G., Carano
R. A., Koeppen. H., Yu. R. X., Forrest, W. F., Plowman, G. D., Johnson, L. (2010) Assessing
therapeutic responses in Kras mutant cancers using genetically engineering mouse models. Nat
Biotechnol. 28:585-93.
6. Bagri, A, Berry L, Gunter B, Singh M, Kasman I, Damico LA, Xiang H, Schmidt M, Fuh G,
Hollister B, Rosen O, Plowman G. D.(2010) Effects of anti-VEGF treatment duration on tumor
growth, tumor regrowth, and treatment efficacy. Clin Cancer Res.16:3887-90.
7. Bostrom J., Yu S, Kan D. Appleton BA, Lee CV, Billeci K, Man W, Peale F, Ross S, Wiesmann
C, Fuh G (2009) Converting Herceptin to a HER2/VEGF bispecific antibodies that inhibits
HER2 and VEGF-dependent tumors. Science 323, 1610-1614.
8. Bostrom, J., Lee, CV, Haber, L, Fuh G. (2009) Improving antibody binding affinity and specificity
for therapeutic development. Methods Mol Biol 525, 1-24.
9. Bostrom, J., and Fuh, G (2009) Design and construction of synthetic phage-displayed Fab
libraries. Methods Mol. Bio. 562:17-36.
10. Berry LR, Barck KH, Go MA, Ross J, Wu X, Williams SP, Gogineni A, Cole MJ, Van Bruggen
N, Fuh G, Peale F, Ferrara N, Ross S, Schwall RH, Carano RA. (2008) Quantification of viable
tumor microvascular characteristics by multispectral analysis. Magn Reson Med. 60, 64-72.
11. Campa C, Kasman I, Ye W, Lee WP, Fuh G, Ferrara N. (2008) Effects of an anti-VEGF-A
monoclonal antibody on laser-induced choroidal neovascularization in mice: optimizing methods
to quantify vascular changes. Invest Ophthalmol Vis Sci. 49, 1178-83.
12. Yu L, Wu X, Cheng Z, Lee CV, Lecouter J, Campa C, Fuh G, Lowman H, and Ferrara N. (2008)
Interaction between Bevacizumab and Murine VEGF-A: A Reassessment. Invest Ophthalmol
Vis Sci. 49, 522-7.
13. Lin WY, Gong, Q Seshasayee, D Lin, Z, Ou Q, Ye S, Suto E, Shu J, Lee WP, Lee CW, Fuh G,
Leabman M, Iyer S, Howell K, Gelzleichter T, Beyer J, Danilenko D, Yeh S, DeForge LE,
Ebens A, Thompson JS, Ambrose C, Balazs M, Starovasnik MA, and Martin F. (2007) Anti-
BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival
blockade. Blood, 110, p3959-67.
14. Korsisaari N, Kasman IM, Forrest WF, Pal N, Bai W, Fuh G, Peale FV, Smits R, and Ferrara N.
(2007) Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of
Apc+/min mice. Proc Natl Acad Sci U S A.104, 10625-30.
15. Gerber, H-P., Wu, X., Yu, L., Wiesmann C., Liang, X. H., Lee, C. V., Fuh, G.. Olsson C., Damico,
L., Xie, D., Meng, Y. G., Guiterrez, J., Peale, V. F., Lee, C. V., Meng, Y. G., Gutierrez, J.,
Corpuz, R., Li B., Hall, L., Rangell, L., Herrandando, R., Lowman, H., Peale, F., Ferrara, N.
(2007) Mice expressing a humanized form of VEGF-A may provide insights into the safety and
efficacy of anti-VEGF antibodies. Proc. Natl. Acad. Sci. USA 104, 3478-83.
16. Fuh, G. Sythetic antibodies as therapeutics (2007) Expert Opin. Biol. Ther. 7, 73-87.
17. Lee, C. V., Hymowitz, S. G., Wallweber, H. J.A., Gordon, N., Billeci, K. L., Tsai, S-P., Compaan,
D. M., Yin, J. P., Gong, Q., Kelley, R. F., DeForge, L. E., Martin, F., Starovasnik, M. A., Fuh,
G. (2006) Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and
murine B cells. Blood 108, 3103-11.
18. Fuh, G., Wu, P., Liang, W-C., Ultsch, M., Lee, C. V., Moffat, B., Wiesmann, C. (2006) Structurefunction
studies of two synthetic anti-VEGF Fabs and comparison with the AVASTIN TM -Fab. J.
Biol. Chem. 281, 6625-31.
19. Liang, W-C., Wu, X., Peale, V. F., Lee, C. V., Meng, Y. G., Gutierrez, J., Fu, L., Malik, A.,
3

Gerber, H-P., Ferrara, N., Fuh, G. (2006) Cross-species blocking antibodies completely inhibit
the growth of human tumor xenografts and measure the contribution of stromal VEGF. J. Biol.
Chem. 281, 951-61.
20. Malik, A. K., Baldwin, M. E, Peale F, Fuh G, Liang WC, Lowman H, Meng G, Ferrara N, Gerber
HP. (2006) Redundant role of VEGF-B and PlGF during selective VEGF-A blockade in mice.
Blood, 107, 550-7.
21. Dong, J., Grunstein, J., Tejada, M.. Peale, F., Frantz, G., Liang, WC., Bai, W., Yi, L., Kowalski, J.,
Liang, X., Fuh, G., Gerber, HP., Ferrara, N. (2004) VEGF-null cells require PDGFR alpha
signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J., 23, 2800-10.
22. Lee, C. V., Liang, W-C., Dennis, M. S., Eigenbrot, C., Sidhu, S. S., Fuh, G. (2004) High-affinity
human antibodies from phage-displayed synthetic Fab libraries with a single framework
scaffold. J. Mol. Biol. 340, 1073-93.
23. Sidhu, S. S., Li, B., Chen, Y., Fellouse, F. A., Eigenbrot, C., Fuh, G. (2004) Phage-displayed
antibody libraries of synthetic heavy chain complementarity Determining regions. J Mol. Biol.
338, 299-310.
24. Lee, C. V., Sidhu, S. S., Fuh, G. (2004) Bivalent Antibody phage display mimics natural
immunoglobulns J. Immunol. Met. 284, 119-132.
25. Christinger, H. W., Fuh, G., de Vos, A. M., Wiesmann, C. (2004) The crystal structure of placental
growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1. J.
Biol. Chem. 279. 10382-8.
26. Yang, S., Toy, K., Ingle, G., Zlot, C., Williams, P. M., Fuh, G., Li, B., de Vos, A. & Gerritsen, M.
E. (2002). Vascular endothelial growth factor-induced genes in human umbilical vein
endothelial cells: relative roles of KDR and Flt-1 receptors. Arterioscler Thromb Vasc Biol 22,
1797-803.
27. Yang, S., Xin, X., Zlot, C., Ingle, G., Fuh, G., Li, B., Moffat, B., de Vos, A. M. & Gerritsen, M. E.
(2001). Vascular endothelial cell growth factor-driven endothelial tube formation is mediated by
vascular endothelial cell growth factor receptor-2, a kinase insert domain-containing receptor.
Arterioscler Thromb Vasc Biol 21, 1934-40.
28. Li, B., Fuh, G., Meng, G., Xin, X., Gerritsen, M. E., Cunningham, B. & de Vos, A. M. (2000).
Receptor-selective variants of human vascular endothelial growth factor. Generation and
characterization. J Biol Chem 275, 29823-8.
29. Fuh, G., Garcia, K. C. & de Vos, A. M. (2000). The interaction of neuropilin-1 with vascular
endothelial growth factor and its receptor flt-1. J Biol Chem 275, 26690-5.
30. Fuh, G., Pisabarro, M. T., Li, Y., Quan, C., Lasky, L. A. & Sidhu, S. S. (2000). Analysis of PDZ
domain-ligand interactions using carboxyl-terminal phage display. J Biol Chem 275, 21486-91.
31. Fuh, G. & Sidhu, S. S. (2000). Efficient phage display of polypeptides fused to the carboxyterminus
of the M13 gene-3 minor coat protein. FEBS Lett 480, 231-4.
32. Pearce, K. H., Jr., Cunningham, B. C., Fuh, G., Teeri, T. & Wells, J. A. (1999). Growth hormone
binding affinity for its receptor surpasses the requirements for cellular activity. Biochemistry 38,
81-9.
33. Hymowitz, S. G., Christinger, H. W., Fuh, G., Ultsch, M., O'Connell, M., Kelley, R. F.,
Ashkenazi, A. & de Vos, A. M. (1999). Triggering cell death: the crystal structure of
Apo2L/TRAIL in a complex with death receptor 5. Mol Cell 4, 563-71.
34. Chen, Y., Wiesmann, C., Fuh, G., Li, B., Christinger, H. W., McKay, P., de Vos, A. M. &
Lowman, H. B. (1999). Selection and analysis of an optimized anti-VEGF antibody: crystal
structure of an affinity-matured Fab in complex with antigen. J Mol Biol 293, 865-81.
35. Fuh, G., Li, B., Crowley, C., Cunningham, B. & Wells, J. A. (1998). Requirements for binding and
signaling of the kinase domain receptor for vascular endothelial growth factor. J Biol Chem 273,
11197-204.
36. Fairbrother, W. J., Christinger, H. W., Cochran, A. G., Fuh, G., Keenan, C. J., Quan, C., Shriver,
S. K., Tom, J. Y., Wells, J. A. & Cunningham, B. C. (1998). Novel peptides selected to bind
4

vascular endothelial growth factor target the receptor-binding site. Biochemistry 37, 17754-64.
37. Wiesmann, C., Fuh, G., Christinger, H. W., Eigenbrot, C., Wells, J. A. & de Vos, A. M. (1997).
Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor.
Cell 91, 695-704. (co-first author)
38. Clark, R., Olson, K., Fuh, G., Marian, M., Mortensen, D., Teshima, G., Chang, S., Chu, H.,
Mukku, V., Canova-Davis, E., Somers, T., Cronin, M., Winkler, M. & Wells, J. A. (1996).
Long-acting growth hormones produced by conjugation with polyethylene glycol. J Biol Chem
271, 21969-77.
39. Fuh, G. & Wells, J. A. (1995). Prolactin receptor antagonists that inhibit the growth of breast
cancer cell lines. J Biol Chem 270, 13133-7.
40. De Vos, A. M., Ultsch, M. H., Kossiakoff, A. A., Fuh, G., Cunningham, B. C., and Wells, J. A.
(1995). Rational design of potent antagonists to the human growth hormone receptor. In:
Shiverick and Rosenbloom (eds.) Human Growth Hormone Pharmacology, Basic and Clinical
Aspects. CRC press, pp. 29-41
41. Wells, J. A., Cunningham, B. C., Fuh, G., Lowman, H. B., Ultsch, M., and De Vos, A. M. (1994).
The molecular endocrinology of human growth hormone. In: Bercu and Walker (eds) Serono
Symposia on Growth Hormone, Growth Hormone II, pp. 231-241.
42. Wells, J. A., Cunningham, B. C., Fuh, G., Lowman, H. B., Bass, S. H., Mulkerrin, M. G., Ultsch,
M. & deVos, A. M. (1993). The molecular basis for growth hormone-receptor interactions.
Recent Prog Horm Res 48, 253-75.
43. Fuh, G., Colosi, P., Wood, W. I. & Wells, J. A. (1993). Mechanism-based design of prolactin
receptor antagonists. J Biol Chem 268, 5376-81.
44. Fuh, G., Cunningham, B. C., Fukunaga, R., Nagata, S., Goeddel, D. V. & Wells, J. A. (1992).
Rational design of potent antagonists to the human growth hormone receptor. Science 256, 1677-
80.
45. Fu, Y. K., Arkins, S., Fuh, G., Cunningham, B. C., Wells, J. A., Fong, S., Cronin, M. J., Dantzer,
R. & Kelley, K. W. (1992). Growth hormone augments superoxide anion secretion of human
neutrophils by binding to the prolactin receptor. J Clin Invest 89, 451-7.
46. Fuh, G., Mulkerrin, M. G., Bass, S., McFarland, N., Brochier, M., Bourell, J. H., Light, D. R. &
Wells, J. A. (1990). The human growth hormone receptor. Secretion from Escherichia coli and
disulfide bonding pattern of the extracellular binding domain. J Biol Chem 265, 3111-5.
47. Cunningham, B. C., Bass, S., Fuh, G. & Wells, J. A. (1990). Zinc mediation of the binding of
human growth hormone to the human prolactin receptor. Science 250, 1709-12.
48. Fuh, G., Bensch, K., Karasek, M. A. & Kramer, R. H. (1986). Synthesis of basement membranespecific
macromolecules by cultured human microvascular endothelial cells isolated from skin
of diabetic and nondiabetic subjects. Microvasc Res 32, 359-70.
49. Kramer, R. H., Fuh, G., Hwang, C. B., Conant, M. A. & Greenspan, J. S. (1985). Basement
membrane and connective tissue proteins in early lesions of Kaposi's sarcoma associated with
AIDS. J Invest Dermatol 84, 516-20.
50. Kramer, R. H., Fuh, G., Bensch, K. G. & Karasek, M. A. (1985). Synthesis of extracellular matrix
glycoproteins by cultured microvascular endothelial cells isolated from the dermis of neonatal
and adult skin. J Cell Physiol 123, 1-9.
PATENT Issued
1. Fuh, G., Gerber, H-P., Liang, W., Fellouse, F., Sidhu, S., Wiesmann, C. (2012) Anti-VEGF
antibodies (8101177)
2. Fuh, G., Gerber, H-P., Liang, W., Fellouse, F., Sidhu, S., Wiesmann, C. (2012) Anti-VEGF
antibodies (8092797)
3. Fuh. G. & Sidhu, S. S. (2011) Synthetic Antibody Phage Libraries (7985840)
4. Fuh, G. & Lee, C. V. (2008) Anti-VEGF antibodies (7910098)
5

5. Fuh, G., Gerber, H-P., Liang, W., Fellouse, F., Sidhu, S., Wiesmann, C. (2006) Anti-VEGF
antibodies (7811785)
6. Fuh, G., Gerber, H-P., Liang, W., Fellouse, F., Sidhu, S., Wiesmann, C. (2006) Anti-VEGF
antibodies (7691977)
7. Fuh, G., Gerber, H-P., Liang, W., Fellouse, F., Sidhu, S., Wiesman, C. (2006) Anti-VEGF
antibodies (7758859)
8. Ackerly, H., Ashkenazi, A., Eberhard, D., Frantz, G., French, D., Fuh, G., Hongo, J-A., Lee, C. V.,
Marsters, S. A., Pitti, R., Raab, H. A., Soroceanu, L., Varfolomeev, E., Wolf, B. B. (2004)
Composition and methods relating to STOP-1 (7799899)
9. Cunningham, B. B., Lowman, H. B., Wells, J. A., Clark, R. G., Fuh, G. (1996) Human Growth
Hormone Variants (5849535)
10. Fuh, G. & Wells, J. A. (1994) Ligand antagonists for treatment of breast cancer (6429186)
11. Cunningham, B. B., Lowman, H. B., Wells, J. A., Clark, R. G., Olsen, K., Fuh, G. (1998) Methods
for inhibiting growth hormone action (6057292)
12. Cunningham, B. B., Lowman, H. B., Wells, J. A., Clark, R. G., Olsen, K., Fuh, G. (1998) Methods
for inhibiting growth hormone action (6004931)
13. Cunningham, B. B., Lowman, H. B., Wells, J. A., Clark, R. G., Olsen, K., Fuh, G. (1998) Human
growth hormone variants comprising amino acid substitutions (6136563)
Published Patent Applications
1. Fuh, G., Haber, L., Schaefer, G., Sliwkowski M. X. (2010) Anti-HER antibodies (20100255010)
2. Fuh, G., Lee, C. V. (2011) Anti-VEGF antibodies (20110159009)
3. Bagri, A., Fuh, G., Lee, C. V. (2010) Anti-VEGF-C antibodies and methods using same
(20110143428)
4. Fuh, G. & Bostrom J. (2007) Multispecific antibodies (20080069820)
5. Fuh, G. & Bostrom J. (2009) Multispecific antibodies (20100322946)
6. Fuh, G. & Bostrom J. (2011) Multispecific antibodies (20110142852)
7. Fuh, G. and Sidhu, S. S. (2004) Synthetic antibody phage libraries (20050119455)
8. Kelley, R. F., Shen, A. Y., Reilly, D., Dennis, M. S., Fuh, G., Lee, C. V., Ambrose, C. M.,
Thompson, J. S. (2010) Altered BR-3 Binding Polypeptides (US20100166741)
9. Ambrose, C. M., Balazes, M., Deforge, L. Dennis, M. S., Fuh, G., Hurst, S. D., Lee, C. V.,
Lowman, H., Martin, F., Nakamura, G. R., Seshasayee, D., Starovasnik, M., Thompson, J. S.
(2010) Polypeptides that binds BR3 and uses thereof (20100280227)
10. Ambrose, C. M., Balazes, M., Deforge, L. Dennis, M. S., Fuh, G., Hurst, S. D., Lee, C. V.,
Lowman, H., Martin, F., Nakamura, G. R., Seshasayee, D., Starovasnik, M., Thompson, J. S.
(2005) Polypeptides that binds BR3 and uses thereof (20080181888)
PRESENTATION (as invited speaker)
1. PEP talk: Antibodies for the 21 st Century (2013) Palm Spring CA
2. 8 th Annual PEGS (2012) Boston
3. IBC’s 22 nd Annual Antibody Engineering Conference (2011) San Diego
4. World Bispecific Antibody Summit (2011) Boston
5. IBC’s Next Generation Protein Therapeutic Summit (2011) San Francisco
6. 241 st American Chemical Society (ACS) National Meeting (2011) Anaheim CA.
7. EMBL-EBI workshop (April 2011) Cambridgeshire, UK
8. Pfizer GBT Lectures (Oct 2010) Boston
9. 25 th Annual meeting of International Society for Biological Therapy of Cancer (2010) Washington
D.C.
10. 24 th Symposium of Protein Society (2010) San Diego
11. SBS Symposium on BioPharmaceuticals: Exploring Synergy Across Drug Formats (2010) San
Francisco
6

12. The 15 th International Conference on Human Antibody and Hybridoma (2010) Porto, Portugal
13. AACR-NCI-EORTC International Conference, on Molecular Targets and Cancer Therapeutics
(Nov 2009) Boston
14. IBC’s Beyond Antibody and Protein Engineering (Sept 2009) San Diego
15. IBC’s 20 th Annual International Conference Antibody Engineering (Dec. 2009) San Diego
16. 5 th annual European Antibody Congress (Nov. 2009) Geneva Switzerland
17. CABS symposium (April, 2009) Converting Herceptin to dual specific antibodies (San Francisco)
18. PEG Summit (April, 2008) Synthetic antibodies (Boston)
19. Bayor’s Antibody Symposium (Nov 2008). The versatile antibody combining site (San Francisco)
20. Cold Spring Harbor Course lecturer: Phage display of proteins and peptides (Nov 2008)
21. GTC’s 3 rd Modern Drug and Disc. & Dev. Summit (Nov. 2007) Synthetic antibodies as therapeutics
(San Francisco)
22. Cold Spring Harbor Course lecturer: Phage display of proteins and peptides (Nov 2007)
23. Cancer Drugs and Angiogenesis, 4 th annual GTCbio conference (Feb. 2007) VEGF antibodies from
synthetic antibody libraries (Philadelphia, PA)
24. Synthetic antibodies as therapeutics (Dec. 2006) 2 nd Modern Drug Disc. & Dev. Summit on
Antibody
25. Synthetic antibodies reveal the role of VEGF in tumorigenesis mouse models (2005) Strategic
Research Institute (SRI) conference on “Monoclonal antibodies in Cancer” (Boston)
26. IBC’s 15 th annual international conference on Antibody Engineering. (Dec. 2004) One hotspot,
many solutions: phage’s answers for VEGF inhibitor (San Diego, CA)
27. CHI’s 6 th annual phage display technology meeting on “Engineering protein therapeutics” (2004) A
blocking anti-VEGF antibody with receptor-like epitope from phage libraries
28. Cross reactive antibodies for target validation from phage-displayed library (2004) Infocast
conference on “Therapeutic antibodies”
29. Synthetic antibody phage libraries go natural (2003) IBC’s annual meeting on “Therapeutic
antibodies”
30. Synthetic antibody phage libraries go natural (2002) SRI’s “Antibody World Summit”
7